elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Pricing
Log in
Sign up
Home
/
Subjects
/
Antibody-drug conjugate
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Antibody-drug conjugate
RIS
0.001
(Research Intensity Score)
Papers
173
Top papers
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
2023 · 457 citations
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines
2025 · 191 citations
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
2023 · 234 citations
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
2023 · 378 citations
Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
2025 · 115 citations
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
2025 · 76 citations
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
2026 · 58 citations
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
2021 · 542 citations
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial
2025 · 48 citations
Newest papers
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
2026 · 58 citations
Tumor Targeting with Peptide-Drug Conjugates: Showcasing Key Progress and Hurdles
2026 · 4 citations
Mocertatug rezetecan (GSK5733584), a B7-H4-targeted antibody-drug conjugate (ADC), in platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC): First results from the global BEHOLD-1 study
2026 · 3 citations
A randomized phase II trial of mirvetuximab soravtansine in folate receptor alpha (FRα)–high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA/AGO-OVAR 2.34).
2026 · 2 citations
Mirvetuximab Soravtansine: Mechanism of Action, Clinical and Translational Science
2026 · 3 citations
Comparative In Vitro Evaluation of Anti-HIV Immunotoxin, Antibody–Drug Conjugate, and Radioimmunoconjugate Targeted by the Same Antibody
2026 · 2 citations
Development and validation of a semi-automated hybrid immunocapture liquid chromatography-mass spectrometry method to quantify LALA-mutated biotherapeutics in mouse plasma
2026
Synergistic lethality of combination treatment with Trop2-directed antibody-drug conjugate sacituzumab govitecan and TRAIL agonists in triple negative breast cancer
2026
Payload-Free[89Zr]Zr-DFO*-sq-EnfortumabImmunoPET for Imaging Nectin-4 Expression in Bladder Cancer
2026
Browse all papers →
Antibody-drug conjugate's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Antibody-drug conjugate's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link